Pharmaceutical Lipid-Based Excipients Market Size, Share & Trends Analysis Report By Excipient Type, By Product Applications, By Disease Application, By Industry Application, By Age Group, By End-use, By Region, And Segment Forecasts, 2025 - 2030

Market Size & Trends

The global pharmaceutical lipid-based excipients market size was estimated at USD 1.82 billion in 2024 and is projected to grow at a CAGR of 4.8% from 2025 to 2030. The growing prevalence of poorly soluble drug candidates, which account for nearly 39% of marketed drugs and 87% of pipeline candidates, has led to a surge in the adoption of advanced excipient solutions. According to a 2023 study published in the European Journal of Pharmaceutical Sciences, supersaturated lipid-based formulations enhance drug absorption for candidates with poor biopharmaceutical properties.

The integration of lipid-based excipients in mRNA vaccines and gene therapies has been a game-changer, particularly in the development of mRNA vaccines during the COVID-19 pandemic. A formulation scientist specializing in nucleic acid-based drugs stated that the adoption of lipid excipients in RNA-based therapies marks a transformative phase in pharmaceutical development. The increasing demand for lipid excipients has also been driven by patent expirations for major pharmaceutical drugs, which has intensified competition and reduced drug prices, further increasing the demand for cost-effective excipients.

Advancements in artificial intelligence (AI) and formulation technologies have also contributed to the growth of the lipid excipients market. The integration of AI-driven modeling can accelerate the development of lipid-based formulations, enhancing predictability and reducing time-to-market. In addition, the emergence of novel excipients and formulation technologies has further increased the potential for successful lipid-based formulations. According to a 2023 study published in the Saudi Pharmaceutical Journal, lipid excipients can enhance the bioavailability of lipophilic drugs by improving their solubility and distribution, thereby reducing potential toxicity.

Furthermore, regulatory bodies have adjusted guidelines as new information is obtained, and expectations for lipid excipients are high due to potential interactions between the lipid excipient and the active ingredient, biological surroundings, and container closure systems. To comply with regulatory requirements, manufacturers must focus on characteristics such as purity and safety. Despite the pressure to generate data, regulatory expectations have remained high, with a focus on patient safety being the top priority.

Excipient Type Insights

The oils segment dominated the market with a share of 40.5% in 2024, driven by rising demand across pharmaceutical, personal care, and industrial sectors. This growth stems from advancements in lipid-based drug delivery, nutraceutical adoption, and a shift towards sustainable ingredients. PURECO oils from ABITEC, refined vegetable oils, are crucial, providing melting and lubrication for diverse applications such as pharmaceuticals and fiberglass.

The lecithin and phospholipids segment is projected to grow at a robust CAGR of 5.5% over the forecast period, propelled by ongoing research addressing the challenges of high molecular weight proteins and peptides. These drugs often require innovative delivery systems, such as slow-release depot injections, to overcome degradation and poor permeation issues. For instance, in August 2024, CRODA Korea Ltd. obtained an EXCiPACT GMP and GDP Certificate from SGS for designing and manufacturing natural and synthetic phospholipids, including lecithin, as pharmaceutical excipients.

Product Applications Insights

Topical formulations led the market with a market share of 51.4% in 2024, driven by innovative products enhancing stability, texture, and patient compliance. As the demand for patient-friendly topical treatments grows in dermatology and mucosal applications, the market benefits from these advancements. Lipid based excipients play a crucial role in this growth, with versatile products such as Emulfree Duo expanding the potential of topical formulations. This trend is expected to continue, driven by the need for effective and easy-to-use treatments, making lipid-based excipients a vital component in the segment’s growth.

Ophthalmic applications are expected to witness the fastest CAGR of 6.7% over the forecast period, fueled by the increasing incidence of dry eye disease. The global aging population and environmental factors have led to higher rates of dry eye syndrome, creating a demand for effective treatments. Lipid-based excipients play a crucial role in ophthalmic formulations, such as eye drops and emulsions, improving solubility, stability, and patient comfort, further driving the segment’s growth.

Disease Application Insights

The oncology segment held the largest market share of 42.3% in 2024, driven by the expanding pipeline of anti-cancer drugs such as targeted therapies and immunotherapies. This growth fuels the demand for excipients improving solubility, stability, and bioavailability. Lipid-based nanoparticles and micelles are now widely used to encapsulate chemotherapeutic agents, ensuring controlled release and reduced toxicity. These excipients are crucial for delivering hydrophobic cancer drugs and enhancing their therapeutic effectiveness. Medium-chain triglycerides (MCTs) and hydrogenated vegetable oils are commonly used in oral oncology formulations to ensure bioavailability and stability. Oncology represents a promising area for lipid-based excipients.

Cardiovascular diseases (CVDs) are expected to grow significantly over the forecast period. As the aging population and the incidence of conditions such as hypertension, atherosclerosis, and heart failure continue to rise, the market for lipid excipients in cardiovascular treatments is expected to expand significantly.As CVDs remain a leading cause of death globally, the market for lipid excipients in cardiovascular treatments is expected to expand. Although mortality rates for CVDs have declined in European countries since 2024, disparities persist between high-income and middle-income countries, as reported by the European Society of Cardiology.

Industry Application Insights

The pharmaceutical (OTC & Rx) segment dominated the market with a share of 61.0% in 2024. Strategic collaborations between drug developers and lipid excipient manufacturers have aided segment growth. These partnerships are crucial for advancing innovative formulations in vaccines, gene therapy, and targeted therapeutics. The pharmaceutical market is experiencing growth fueled by these collaborations. For instance, In February 2024, a study in the Journal of Chemical and Pharmaceutical Research highlighted advancements in formulation strategies and delivery technologies for hydrophobic drugs. The research focused on enhancing solubility and permeability, crucial for oral drug delivery.

The nutraceutical (dietary supplements & others) segment is expected to witness the fastest CAGR of 5.1% over the forecast period. This expansion is largely driven by strategic collaborations between lipid excipient manufacturers and pharmaceutical companies specializing in supplements. These collaborations are coupled with expanded distribution agreements, significantly broadening market access. This synergistic approach leverages the formulation expertise of lipid excipient manufacturers and the market presence of supplement-focused pharmaceutical firms. This dual strategy fuels the increased integration of lipid excipients within dietary supplements and functional foods.

Age Group Insights

The adult products (19-64 years) segment dominated the market with a share of 59.6% in 2024. Increased demand for effective treatments for cardiovascular disease, diabetes, and neurodegenerative disorders is boosting the adoption of lipid-based formulations. These formulations enhance drug solubility, stability, and bioavailability, thereby addressing critical challenges in pharmaceutical development and improving therapeutic outcomes.

The geriatric products (65+ years) segment is expected to witness the fastest CAGR of 5.2% over the forecast period. As aging-related conditions become more widespread, the demand for specialized drug delivery systems, including lipid-based formulations, continues to grow. According to the NIH, 85% of this demographic has at least one chronic condition. Pharmaceutical companies are developing specialized drug delivery systems, including lipid-based formulations, to enhance bioavailability, stability, and controlled release. Advanced technologies, such as lipid nanoparticles and sustained-release matrices, are being invested in to improve treatment efficacy and patient adherence.

End-use Insights

The pharmaceutical manufacturers segment dominated the market with a share of 64.9% in 2024. Pharmaceutical manufacturers are driving innovation, fueled by the increasing demand for new drug formulations and cutting-edge delivery systems. The production of advanced therapeutics, such as mRNA-based drugs and hormone therapies, is further boosting demand for lipid-based excipients. Investment in research and development is a key driver of growth in the lipid-based excipients market, particularly in the pharmaceutical end-use segment. This trend is expected to continue as the industry continues to evolve.

Contract Development and Manufacturing Organizations (CDMOs) are expected to witness the fastest CAGR of 5.2% over the forecast period. The surge in innovations related to RNA-based therapies has significantly enhanced the market for lipid-based excipients. CDMOs are essential in producing these intricate formulations, serving as key end users by integrating lipid excipients into drug production, particularly for mRNA and gene therapies. This sector generates revenue by providing formulation, production, and regulatory support services, closely linking their growth to the expanding demand for lipid-based excipients in advanced therapeutics.

Regional Insights

North America pharmaceutical lipid-based excipients market held substantial market share in 2024. In North America, the pharmaceutical lipid-based excipients market is expanding driven by the rising demand for advanced drug delivery systems and biologic formulations. These excipients are essential in enhancing the bioavailability of poorly soluble drugs, particularly in oral and parenteral formulations. Market expansion is fueled by the increasing prevalence of chronic diseases, a growing biologics sector, and the need for innovative drug delivery solutions.

U.S. Pharmaceutical Lipid-based Excipients Market Trends

The pharmaceutical lipid-based excipients market in the U.S. dominated the North America pharmaceutical lipid-based excipients market in 2024. Lipid-based excipients enhance the solubility and stability of poorly soluble drugs, driving demand from biologics, biosimilars, and mRNA vaccines. Key U.S. manufacturers such as Lonza, Avanti Polar Lipids, CordenPharma, and BASF are meeting this demand. Market growth is further supported by personalized medicine and a rise in chronic diseases, presenting opportunities for innovation and strategic partnerships.

Europe Pharmaceutical Lipid-based Excipients Market Trends

Europe pharmaceutical lipid-based excipients market dominated the global market with a revenue share of 33.6% in 2024, supported by the increasing adoption of advanced drug delivery systems and the rising burden of chronic diseases. Major markets such as Germany, France, and the UK are key drivers of growth, supported by pharmaceutical innovation and regulatory alignment. Leading manufacturers, including Cargill, Croda International Plc, and W.R. Grace, dominate the market with high-quality lipid excipients such as lecithins, glycerol esters, and solubilizers. The demand for functional excipients is rising, particularly in oral solid dosage forms and biologics.

The pharmaceutical lipid-based excipients market in Germany dominated the Europe market with a revenue share of 20.8% in 2024. The German pharmaceutical industry is globally recognized for its innovation and standards. This has driven demand for lipid-based excipients, essential for enhancing the solubility, stability, and bioavailability of active pharmaceutical ingredients (APIs). These excipients support advanced drug delivery systems, including oral, topical, and parenteral formulations.

Asia Pacific Pharmaceutical Lipid-based Excipients Market Trends

Asia Pacific pharmaceutical lipid-based excipients market is expected to register the fastest CAGR of 5.6% in the forecast period, driven by increasing demand for lipid excipients in advanced drug delivery systems. Countries such as China, India, Japan, and South Korea play crucial roles in pharmaceutical formulation development and production. Lipid excipients, such as lipid nanoparticles and emulsions, are widely used in oral, injectable, and topical drug delivery for improved solubility, bioavailability, and controlled release. China and India lead in cost-effective production and R&D capabilities, while Japan focuses on high-quality lipid-based formulations for oncology, vaccines, and other therapies. South Korea is also rapidly expanding its pharmaceutical sector, emphasizing innovative lipid excipient applications.

The pharmaceutical lipid-based excipients market in China is expected to grow at the fastest rate of 6.1% over the forecast period, fueled by healthcare expansion and innovative drug delivery technologies. Rising chronic diseases and biologic therapies increase demand for excipients improving drug solubility and bioavailability. Local manufacturers such as Shanghai Transfar Zannuo, Jiangsu Hengrui, Sinopharm, and Shandong Lukang are well-positioned to capitalize on this demand, driven by strong regulatory support and a focus on injectable formulations and biologic therapies.

Key Pharmaceutical Lipid-based Excipients Company Insights

Some key companies operating in the market include ABITEC Corporation; BASF; Gattefossé; CordenPharma; Lipoid; and IOI Oleo GmbH; among others. Key players include both large multinational corporations and specialized firms. Growing competition from rising demands for LBDDS, particularly in mRNA vaccines and gene therapies, has spurred strategic partnerships and innovations

• Gattefossé specializes in lipid-based excipients designed to enhance the oral bioavailability of poorly water-soluble drugs. By 2025, their innovative solutions have been widely adopted in formulations from early development to market, significantly reducing development time and improving drug solubilization and stability.

• Croda International PLC offers a broad portfolio of high-purity pharmaceutical excipients, including specialized lipids and surfactants, that improve drug solubility, stability, and delivery. These excipients have aided in developing effective and stable pharmaceutical formulations.

Recent Developments

• In May 2024, CordenPharma and Certest partnered to integrate Certest’s ionizable lipids into CordenPharma’s LNP formulation services. This collaboration supports biotech companies in developing xRNA/xDNA therapies.

• In January 2025, Evonik partnered with ST Pharm (South Korea) to enhance RNA and nucleic acid therapeutic services. This collaboration aims to expedite drug development and streamline processes for pharmaceutical companies globally.

• In November 2024, Gattefossé inaugurated its new Technical Center of Excellence in Mumbai, India. This investment supports the growing Indian pharmaceutical and personal care markets, fostering innovation and collaboration.

Pharmaceutical Lipid-based Excipients Market Report Scope

Global Pharmaceutical Lipid-based Excipients Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global pharmaceutical lipid-based excipients market report based on excipient type, product applications, disease application, industry application, age group, end-use, and region:

• Excipient Type Outlook (Revenue, USD Million, 2018 - 2030)

  • Oils

    • Sesame Oil

    • Soybean Oil

    • Sunflower Oil

    • Linseed Oil / Flaxseed Oil

    • Safflower Oil

    • Coconut Oil

    • Arachis Oil / Peanut Oil

    • Corn Oil / Maize Oil

    • Olive Oil

    • Almond Oil

    • Castor Oil

    • Cotton Seed Oil

    • Grapeseed Oil

    • Other Oils

  • Hydrogenated Vegetable Oils

  • GMCC (Glyceryl Monostearate)

  • Hard Fats

  • Medium Chain Triglycerides (MCTs)

  • Lecithin and Phospholipids

  • Sodium Oleate

  • Capri Caprylic Mono Diglyceride

  • Other Excipient Types

• Product Applications Outlook (Revenue, USD Million, 2018 - 2030)

  • Oral Formulations

    • Softgel Capsules

    • Solid Dosage (Tablet, capsules, & pills)

    • Liquid Oral

    • Solid Lipid Nanoparticles (SLNs)

  • Parenteral

    • Small Volume Parenteral

    • Large Volume Parenteral

  • Topical Applications

    • Creams

    • Ointments

    • Other

  • Ophthalmic Applications

    • Eye Drops

    • Ocular Emulsions

  • Suppositories

    • Rectal Suppositories

    • Vaginal Suppositories

    • Other Suppositories

  • Other Product Applications

• Disease Application Outlook (Revenue, USD Million, 2018 - 2030)

  • Cardiovascular Diseases

  • Neurological Disorders

  • Oncology

  • Metabolic Disorders

  • Hormonal Therapies

  • Infectious Diseases

  • Other Disease Applications

• Industry Application Outlook (Revenue, USD Million, 2018 - 2030)

  • Pharmaceutical (OTC & Rx)

  • Nutraceutical (Dietary Supplements & Others)

• Age Group Outlook (Revenue, USD Million, 2018 - 2030)

  • Pediatric Products (0-18 years)

  • Adult Products (19-64 years)

  • Geriatric Products (65+ years)

• End-use Outlook (Revenue, USD Million, 2018 - 2030)

  • Pharmaceutical Manufacturers

  • Contract Development and Manufacturing Organizations (CDMOs)

  • Other End Users

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Jordan

    • Egypt

    • Iran

    • Kuwait